Metformin Medical Valley (Metformin Hydrochloride)

Metformin is a biguanide oral antidiabetic that targets the underlying mechanisms of insulin resistance and excessive hepatic glucose production, making it a cornerstone therapy for several metabolic conditions.

• Type 2 diabetes mellitus: improves glycemic control by decreasing hepatic glucose output and enhancing peripheral insulin sensitivity, leading to lower fasting and post‑prandial blood glucose levels.
• Polycystic ovary syndrome (off‑label): reduces insulin resistance, which can help restore regular menstrual cycles and improve ovulatory function in affected women.
• Prediabetes (off‑label): may delay progression to type 2 diabetes by improving insulin sensitivity.

• Metformin primarily inhibits mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. The resulting decrease in ATP production activates AMP‑activated protein kinase (AMPK), leading to reduced glucose output by the liver and increased glucose uptake in skeletal muscle. It also improves insulin receptor signaling and modestly lowers intestinal glucose absorption, collectively contributing to lower plasma glucose concentrations.

Metformin may cause a range of adverse reactions, most of which are related to gastrointestinal tolerance or metabolic disturbances.

Common Side Effects

• Nausea: mild to moderate feeling of sickness, often transient.
• Diarrhea: loose stools that may be watery.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal accumulation of lactate, presenting with rapid breathing, muscle pain, and abdominal discomfort.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Vitamin B12 deficiency: long‑term use may lead to decreased absorption, causing anemia.

Before initiating metformin therapy, several precautionary measures should be considered to ensure patient safety and optimal efficacy.

• Renal function assessment: evaluate eGFR prior to start and periodically during treatment.
• Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
• Alcohol consumption: limit intake as alcohol can increase lactic acidosis risk.
• Pregnancy and lactation: discuss potential benefits and risks with a healthcare professional.
• Drug interactions: review concomitant medications for possible interactions that may affect metformin levels.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin interacts with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate renal dysfunction and increase risk of lactic acidosis.
• Cimetidine: can raise metformin plasma concentrations, heightening toxicity risk.
• Nucleoside reverse transcriptase inhibitors (e.g., didanosine): associated with increased incidence of lactic acidosis.
• Alcohol abuse: synergistically elevates lactic acidosis potential.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask symptoms of hypoglycemia.
• Thiazide diuretics: can attenuate metformin’s glucose‑lowering effect.
• Corticosteroids: may reduce metformin efficacy by increasing blood glucose.
• ACE inhibitors/ARBs: require monitoring of renal function when combined.
• Sulfonylureas: combined use can increase risk of hypoglycemia.